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Abstract
Non-small cell lung cancer (NSCLC) is notorious for its paltry responses to first-line therapeutic
regimens. In contrast to acquired chemoresistance, little is known about the molecular
underpinnings of the intrinsic resistance of chemo-naïve NSCLC. Here we report that intrinsic
resistance to paclitaxel in NSCLC occurs at a cell-autonomous level due to the uncoupling of
mitotic defects from apoptosis. To identify components that permit escape from mitotic stress-
induced death, we employed a genome-wide RNAi-based strategy, which combines a high-
throughput toxicity screen with a live-cell imaging platform to measure mitotic fate. This strategy
revealed that prolonging mitotic arrest with a small molecule inhibitor of the APC/Cyclosome
could sensitize otherwise paclitaxel-resistant NSCLC. We also defined novel roles for CASC1 and
TRIM69 in supporting resistance to spindle poisons. CASC1, which is frequently co-amplified
with KRAS in lung tumors, is essential for microtubule polymerization and satisfaction of the
spindle assembly checkpoint. TRIM69, which associates with spindle poles and promotes
centrosomal clustering, is essential for formation of a bipolar spindle. Notably, RNAi-mediated
attenuation of CASC1 or TRIM69 was sufficient to inhibit tumor growth in vivo. On the basis of
our results, we hypothesize that tumor evolution selects for a permissive mitotic checkpoint, which
may promote survival despite chromosome segregation errors. Attacking this adaptation may
restore the apoptotic consequences of mitotic damage to permit the therapeutic eradication of
drug-resistant cancer cells.
Keywords
mitotic slippage; pan-genomic RNAi screen; paclitaxel; CASC1; TRIM69
#Address correspondence to: Angelique Whitehurst, PhD. UT-Southwestern Medical Center 6001 Forest Park Drive, Dallas, TX
75390-8807. Phone (214)-645-6066. 214-645-6347 angelique.whitehurst@utsouthwestern.edu..
*Current Institution: Simmons Comprehensive Cancer Center, UT-Southwestern Medical Center, Dallas, TX.
Conflicts of Interest: The authors have no conflicts of interest to disclose
NIH Public Access
Author Manuscript
Cancer Res. Author manuscript; available in PMC 2015 July 15.
Published in final edited form as:























Paclitaxel is a first-line chemotherapeutic agent that inhibits the dynamic instability of
microtubules, thus preventing bi-orientation of chromosomes during mitosis (1). While the
reduction of breast and ovarian tumor burden following taxane-based therapies demonstrates
efficacy in these settings, responses in NSCLC are rarely curative, as only 30% of patients
exhibit a partial response at best, indicating a widespread intrinsic resistance to anti-mitotic
agents (2, 3). Thus, given the promise, yet limitation, of current anti-mitotic therapies, the
identification of mechanisms supporting intrinsic resistance to paclitaxel in NSCLC is
essential. Our goal here was to identify the cell autonomous components that permit escape
from mitotic stress-induced cell death in a paclitaxel resistant NSCLC setting.
Efficacy of paclitaxel and other anti-mitotic agents hinges on the coupling of mitotic defects
to cell death. By inhibiting the dynamic instability of microtubules, paclitaxel disrupts
chromosome alignment, thereby preventing satisfaction of the spindle assembly checkpoint
(SAC). The SAC is composed of sentinel proteins including MAD2 and BUBR1, which, in
the absence of proper microtubule-kinetochore attachments, inhibit the activity of the
Anaphase Promoting Complex/Cyclosome (APC/C) (4, 5). Nearly all tumor cells are
sensitive to paclitaxel-induced mitotic defects and engage the SAC. However, live-cell
imaging studies have revealed that the length and outcome of this mitotic arrest is variable
within and among tumor cell lines. For example, apoptosis may be activated directly from
mitotic arrest. Otherwise, arrested cells undergo mitotic slippage, defined as an aberrant exit
in the presence of misaligned chromosomes thereby forming micronucleated cells that can
either die, arrest or reenter a subsequent division cycle (6–8). This slippage from an SAC-
mediated mitotic arrest has been implicated as a survival mechanism, as delaying mitotic
exit, either by inhibiting an activator of the APC/C, CDC20, or overexpressing cyclin B1,
can increase mitotic dwell time and cell death during or following mitosis (6, 9). The
prolonged mitotic arrest may allow for accumulation of death signals that trigger apoptosis
(10, 11). However, the molecular components that promote mitotic slippage, particularly in
chemoresistant tumor cell lines are unclear.
Previously, we established a pan-genomic, siRNA-based screening platform to identify gene
products that modulate sensitivity of NSCLC cells to paclitaxel (12). Here, we employ this
platform to investigate the molecular components supporting resistance to paclitaxel in a
NSCLC system that exhibits no loss of viability following exposure to doses as high as 1
μM. At single cell resolution, we find that resistant cells undergo mitotic slippage and
survive as micronucleated cells, indicative that resistance is due to a regulatory setting that
permits the deflection of mitotic stress-induced cell death. In agreement with this notion, a
global screen discovered components, which when depleted, sensitize these chemorefractory
cells to paclitaxel. Suppression of a cohort of these chemosensitizers induced a protracted
mitotic arrest, which we find is essential for post-mitotic cell death. Functional elaboration
of these chemosensitizers reveals that prolonging mitotic arrest can be accomplished either
by direct inhibition of the APC/Cyclosome (APC/C), or through collateral spindle damage,
due to the depletion of CASC1 or TRIM69, which we reveal here are novel regulators of
mitotic spindle assembly in tumor cells. Thus, prolonging mitotic arrest, which can be
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HBEC, NSCLC, 293 and HeLA cell were a gift from John Minna and Michael White. HeLa,
H1299, HCC4017, HCC1171, H1299, H1155 and HBEC lines were validated by Short
Tandem Repeat analysis. NSCLC cell lines were maintained in RPMI medium (Gibco) with
5% fetal bovine serum (FBS). HBEC cell lines were maintained in keratinocyte medium
plus supplements (Gibco). HeLa and 293 cells were maintained in DMEM with 10% FBS.
Paclitaxel (Sigma or Tocris), ProTAME (Boston Biochem) and Nocodazole (Sigma) were
dissolved in Dimethyl Sulfoxide (DMSO). Cell-Titer Glo® (CTG) and APO-ONE® were
obtained from Promega. Dharmafect transfection reagents were obtained from Thermo-
Fisher. Control siRNA transfections were performed with either non-targeting siRNA pool
(Dharmacon) or a pool targeting DLNB14(12).
Paclitaxel Dose Curves
Cell lines were plated in 96-well plates to reach 50% confluence at 48 hours, when they
were exposed to paclitaxel for 48 hours. Cell viability assessed using the Cell-Titer Glo®
assay.
Immunoblotting
Cells were lysed in boiling 2X Laemmli sample buffer and resolved by SDS-PAGE.
Antibodies used as follows: Actin, ANAPC5, CASC1, GAPDH, MCL-1, PDE3B, Myc-A14,
Myc-9E10, GST (Santa Cruz); Cleaved Caspase-3 (Epitomics); MAD2L1 (Covance);
TRIM69, β-tubulin (Sigma); Pericentrin (Abcam); phospho-histone-H3 (Millipore).
Immunofluorescence
Cells were grown on glass coverslips, fixed in 3.7% formaldehyde, permeabilized with 0.5%
Triton X-100 and blocked with PBTA (PBS, 0.1% Tween-20, 10 mg/ml bovine serum
album). Slips were incubated with primary antibodies in PBTA and, following PBTA
washes, incubated with AlexaFluor-conjugated secondary antibodies (Invitrogen). For
BUBR1 staining, cells were fixed in cold methanol. For microtubule preservation, cells were
extracted with BRB80 (80 mM PIPES pH6.8, 1 mM MgCl2, 5 mM EGTA) and 0.5% Triton
X-100 for 30 seconds followed by a 0.5% glutaraldehyde fix and 0.1% NaBH4 quench.
Slides were imaged on an Axioimager upright microscope (Zeiss) equipped with a charge-
coupled device (CCD) camera or a Leica CTR5500 upright scope with a monochrome
digital camera (Leica DFC340 FX). Quantitation of fluorescence was performed with
ImageJ software and normalized to cytoplasmic fluorescence.
Stable cell line production
Cell lines stably expressing green fluorescent protein-histone H2B (GFP-H2B) or myc-
TRIM69A were generated by retroviral transduction. Retrovirus was produced by
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transfection of 293GP cells with vesicular stomatitis virus G protein (VSV-G) and either
pCLNCX-GFP-H2B (gift from Gray Pearson) or pLPCX-myc-TRIM69A. Virus was
harvested 48 hours post-transfection and transduced cells were selected with Geneticin®
(pCLNCX-GFP-H2B) or Puromycin (pLPCX-myc-TRIM69A).
High-content live–cell imaging
Cell lines stably expressing GFP-H2B were transfected in a 96-well plate and exposed to
vehicle or paclitaxel 48 hours post transfection and, unless otherwise indicated, imaged
immediately following the addition of paclitaxel. Imaging was performed on a BD
Pathway™ 855 Bioimager using a 40x or a 20x high-numerical-aperture objective. Images
were taken every 20 minutes for 48–72 hours. Image sequences were generated using
ImageJ and manually quantified.
siRNA screen
A two-condition, triplicate analysis screen was performed in a 96-well plate format using a
Thermo-Fisher library that targets 21,127 unique genes (12). HCC366 cells were transfected
with 40 nM siRNAs for 48 hours, followed by exposure to vehicle or 10 nM paclitaxel for
an additional 48 hours. Subsequently, CTG was added and values were read on an
EnVision® Plate Reader. The screening protocol was identical to that previously described
with the following exceptions: HCC366 cells were seeded at 1×104, transfected with
Dharmafect 2 complexed siRNAs in RPMI medium and cells were treated at 48 hours post
transfection with vehicle or paclitaxel and a final FBS concentration of 10% (12). High
interest chemosensitizers were ranked by z-score (Supplemental methods).
siRNA Transfections
siRNA transfections were performed using Thermo-Fisher of Sigma siRNA pools. Pools
were used at a final concentration of 50 nM for indicated times.
Quantitative Reverse Transcription PCR
Total RNA was collected using the GenElute Mammalian Total RNA Miniprep Kit (Sigma).
2μg total RNA was used in subsequent reverse transcription using the High-Capacity cDNA
reverse transcription kit (Applied Biosystems). Quantitative reverse transcription PCR
(qRT-PCR) was performed with TaqMan gene expression assays and ribosomal protein L27
(RPL27) was the endogenous control.
Colony formation assays
HCC366 cells were transfected in a 24-well format and exposed to 0 and 10 nM paclitaxel
48 hours post-transfection. 96 hours post transfection 2×103 viable cells were replated in a
6-well format. Cells were fed biweekly for up to 3 weeks prior to formaldehyde fixation and
Geimsa staining. Colonies were counted manually.
Microtubule regrowth assay
Cells were exposed to 11 μM nocodazole for 1 hour, 72 hours post-transfection. Cells were
then rinsed with PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM
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MgCl2, 1 μM Paclitaxel) and placed in fresh media to recover for the time indicated. Cells
were then permeabilized with 0.2% Triton X-100 for one minute then fixed and
immunostained.
In vivo polymerized tubulin assay
72 hours post-transfection, cells were lysed in microtubule stabilizing buffer (100 mM
PIPES, 2 M glycerol, 0.1 M MgCl2, 2 mM EGTA, 0.5% TritonX-100, 5 μM Paclitaxel).
Subsequently, whole cell lysates samples were collected and centrifuged for 30 minutes at
4°C and 16,000g. The supernatant (monomeric tubulin) was collected and pellet
(polymerized tubulin) resuspended in microtubule stabilizing buffer. Fractions were
resolved by SDS-PAGE.
cDNA expression and plasmids
Cells were transfected with cDNA expression vectors using Lipofectamine 2000
(Invitrogen). Plasmids used: Tomato-H2B, pCMV-myc (Clontech), mCMV-myc-TRIM69A,
pCMV-myc-TRIM69B and pCMV-myc-TRIM69A(C50S/C53S).
Tumor Xenografts
pLKO.1 vectors expressing short hairpin RNA (shRNA) were used to generate lentivirus to
infect HCC366 cells. Target knockdown was assessed 72 hours post-infection. Cells were
harvested 96 hours post-infection and 2 ×106 cells were injected into the flank of female
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX®) mice. 3 ×106 cells were used for taxol
studies. All mice were maintained in sterile conditions according to an approved IACUC
protocol and abiding by all UNC Animal Welfare guidelines. Tumor growth was monitored
by caliper measurement at indicated time points. In paclitaxel experiments, mice were
treated with 20 mg/kg of paclitaxel starting 10 days post injection, at a frequency of two
days per week for 4 weeks.
Hematoxylin and eosin staining (H&E)
Tumors from xenograft mouse studies were excised and formalin fixed and paraffin
embedded. Tissue was processed by routine microtomy into 5–6 micron sections for
automated staining. At least 7 fields were manually quantitated for micronucleated cells.
TUNEL staining
Terminal deoxynucleotidyltransferase-mediated UTP end label (TUNEL) staining for
apoptotic cells in tissue sections was performed using the DeadEnd Fluorometric TUNEL
System (Promega) standard protocol. Apoptotic cells were labeled with fluorescein, and the
sections were counterstained with propidium iodide. At least 6 fields were counted per
sample.
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Pan-genomic screening reveals components that liberate tumor cells from mitotic stress
induced death
As a discovery platform for identifying mechanisms that promote resistance to paclitaxel-
induced cell death, we selected HCC366 cells, a member of a cohort of NSCLC cell lines,
which undergo limited viability loss and no activation of caspase-3 following exposure to
escalating doses of paclitaxel (Figure 1A and B). While cell lines in this cohort exhibit
minimal viability loss following paclitaxel exposure, a 10 nM dose is sufficient to induce
multipolar spindles, misaligned chromosomes, and generate micronucleated progeny (Figure
1C, Supplemental 1A). Indicating that these cells have an intact SAC, live-cell imaging
studies demonstrated that paclitaxel induced a MAD2 and BUBR1 dependent mitotic arrest
that uniformly led to mitotic slippage and the generation of micronucleated progeny (Figure
1D). Single cell lineage tracing of HCC366 micronucleates, beginning 72 hours post
paclitaxel exposure, revealed that the majority (92%) of these cells continued to survive for
40 hours and 8 % successfully underwent a subsequent division cycle (Figure 1E,
Supplemental Figure 1B, Supplemental Video 1). Replating assays revealed that 40–50 % of
treated cells were capable of colony formation, indicating that these cells, despite mitotic
damage, maintain the capacity to proliferate (Supplemental Figure 1C). In contrast, a
representative sensitive cell line, H1155, undergoes a dramatic mitotic arrest resolved by
either cell death or micronucleation at 100 nM (Supplemental Figure 1D). The HCC366
mitotic slippage response was also recapitulated in vivo, as tumors grown subcutaneously in
immune deficient mice exposed to paclitaxel were composed of micronucleated cells (Figure
1F). This finding suggests that HCC366 cells harbor a regulatory context in which mitotic
stress is uncoupled from tumor cell death, leading to paclitaxel resistance and continued
tumor cell proliferation.
To comprehensively investigate the molecular basis for deflection of paclitaxel-induced
death, we performed a pan-genomic, siRNA-based loss of function screen in the presence
and absence of 10 nM paclitaxel in HCC366 cells (Supplemental Figure 1E and F). This
analysis returned 49 candidate siRNA pools with a z-score of < −2.5 that correspond to
annotated genes in the human GENE database (see Supplementary Methods, Supplementary
Table 1 and Supplementary Table 2).
We further stratified these siRNAs using a secondary screening strategy to measure
caspase-3/7 activity and mitotic transit time for 23 candidates selected from diverse
functional categories (Figure 2A, Supplemental Figure 2A&B, Supplementary Table 1).
Target mRNA knockdown was also evaluated (Supplemental Figure 2C). This counter
screen returned nine targets whose inhibition activated apoptotic signaling, four of which
increased mitotic transit time at least 20%. Colony formation assays revealed a 50%
decrease in replating efficiency, indicating that the cell death observed was sufficient to
reduce survival of the population (Figure 2B). This finding indicated that even in slippage
prone NSCLC, a number of molecular mechanisms exist to enhance SAC robustness. Thus,
we focused on this cohort of ANAPC5, PDE3B, CASC1 and TRIM69 for further
mechanistic elaboration. All four of these siRNA pools met our off-target validation criteria
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of two independent siRNAs or non-redundant pools reproducing the apoptotic phenotype
(Supplementary Figure 2D).
Single-cell lineage tracing revealed that the prolonged mitotic arrest in target depleted cells
resolved as mitotic slippage to generate micronucleated progeny; 40–50% of which
subsequently died as measured by cell blebbing and a loss of movement (Figure 2C).
Indicative of a functional conservation of these genes across multiple genetic backgrounds,
their inhibition enhanced paclitaxel-induced mitotic arrest in HCC1171, HCC515 and
H2887, cell lines that also exhibit a deflection of mitotic stress induced death (Supplemental
Figure 2E). Thus, prolonging mitotic arrest induced a post-mitotic apoptotic response.
Restoring paclitaxel sensitivity requires a protracted mitotic arrest
Of these validated genes, ANAPC5 is the best characterized as encoding a scaffold in the
multi-protein APC/Cyclosome complex, whose inhibition attenuates the proteolytic cascades
required for anaphase onset (13). While roles for CASC1, TRIM69 and PDE3B in mitosis
have not been described, their identification in a cohort with ANAPC5 suggests that they
may contribute to APC/C inhibition. Indeed, co-depletion of CASC1, TRIM69 or PDE3B
with MAD2 significantly reduced mitotic transit time in the presence of paclitaxel
(Supplemental Figure 3A). Co-depletion also rescued micronucleated cell death as assessed
by live-cell imaging and cleaved-caspase-3 protein levels (Figure 2D, Supplemental Figure
3B).
The pro-survival protein, MCL-1, is degraded during a prolonged mitosis and has been
implicated as a regulator of apoptosis following exposure to anti-mitotic therapeutics (10,
11). Depletion of CASC1 or TRIM69 leads to a reduction in MCL-1 levels in a paclitaxel
dependent manner while PDE3B inhibition led to a reduction in MCL-1 even in the absence
of paclitaxel. Consistent with previous reports indicating that MCL-1 is degraded by residual
APC/C activity during mitosis, siANAPC5 did not decrease MCL-1 levels (10) (Figure 2E).
Cell death despite MCL-1 stabilization in ANAPC5 depleted cells indicates existence of
MCL-1 independent apoptotic mechanisms. Taken together, these findings suggest that
enhancing mitotic arrest by 20–50% in the presence of paclitaxel can be sufficient to engage
a programmed cell death response in chemoresistant NSCLC.
Inhibition of APC/C is synthetic lethal with paclitaxel in chemorefractory NSCLC
Findings thus far indicate that, in principle, prolonging mitotic arrest by inhibiting the
APC/C may be a therapeutic strategy to restore paclitaxel sensitivity in NSCLC.
Importantly, suppression of ANAPC5 in non-tumorigenic cells (HBEC3KT) did not enhance
the impact of paclitaxel, suggesting that tumor cells may have an enhanced sensitivity to
APC/C inhibition (Figure 2F). The difference in response is unlikely due to cell cycle
kinetics as the HBEC3KT and HCC366 cells proliferate at approximately the same rate
(Supplemental Figure 3C). Together these data suggest that this combinatorial approach may
exhibit a therapeutic window. Indeed, combining a sub-lethal dose of the APC/C inhibitor,
proTAME, with paclitaxel in HCC366 cells enhanced the accumulation of mitotic cells and
induced cleaved-caspase 3/7 above levels detected for either agent alone (Figure 2G,
Supplemental Figure 3D) (14).
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To further examine molecular mechanisms that contribute to the duration of mitotic arrest,
we focused on CASC1 and TRIM69, whose inhibition displayed minimal, if any, single
agent activity, but which collaborated with paclitaxel to both increase mitotic transit time
and reduce MCL-1 levels.
CASC1 regulates microtubule function
While limited information is available on the function of human CASC1, a polymorphism in
the murine Casc1 gene at codon 60 (AGT (Ser) -> AAT (Asp)) is associated with
susceptibility to urethane-induced lung carcinogenesis in mouse models (15, 16). The
significance of these polymorphisms has not been realized in human cancer as none of the
five human CASC1 isoforms harbor Asn or Ser at residue 60, and other polymorphisms in
CASC1 have not been linked to NSCLC susceptibility or progression (17). However, TCGA
analysis revealed an amplification of CASC1 in 15%, 11%, and 7% of lung (adenoma &
squamous), ovarian and breast tumors, respectively (Supplemental Figure 4A)(18). This
amplification typically co-occurs with KRAS, which is adjacent to CASC1 on chromosome
12. While the function of human CASC1 has not been documented, returning this gene as a
top paclitaxel sensitizer in a genome-wide screen implies it may have essential roles in
supporting cell division. We assessed the consequences of CASC1 depletion alone and in
the presence of an otherwise innocuous dose of paclitaxel in a panel of NSCLC lines with
differing paclitaxel sensitivity. In resistant cell lines, where we detected mitotic arrest
phenotypes, we found a dependence on CASC1 for viability alone or in the presence of
paclitaxel (Figure 3A). Additionally, siCASC1 is monogenic lethal or synthetic lethal with
paclitaxel in 5 additional NSCLC cell lines, a defect we did not observe in an immortalized
human bronchial epithelial (HBEC3KT) cell line (Figure 3A). Thus, CASC1 appears to be
essential in both resistant and sensitive tumor settings, indicating that tumor cells develop a
dependence on this protein for mitotic progression. Examination of individual cells indicated
that CASC1 is essential for mitotic spindle integrity as inhibition led to: 1) exacerbation of
the frequency of spindles with >2 pericentrin positive foci in HCC366 cells, 2) generation of
multipolar or miniature spindles in H1299 cells and 3) induction of aberrant mitotic spindles
in the presence of an otherwise innocuous dose of paclitaxel in H1155 cells (Figure 3B and
Supplemental Figure 4B). Live-cell imaging of H1155 cells indicated that depletion of
CASC1 prolonged mitotic arrest, which resolved as either aberrant mitotic exit or cell death
in the presence of paclitaxel (Supplemental Figure 4C).
Previous reports indicate that murine and chlamydomonas CASC1 (IC97) orthologues can
bind microtubules (15, 19). Given that human and mouse CASC1 proteins are 66.7%
identical and 92% identical in the microtubule binding region, we reasoned that the mitotic
defects observed following CASC1 depletion could be due to a microtubule defect. We
examined the microtubule network in H1299 cells, where siCASC1 alone had a potent
impact on mitotic spindle formation and cell viability. siCASC1 diminished the polymerized
tubulin network in interphase cells and attenuated microtubule regrowth after nocodazole
washout (Figure 3C and 3D). Recently, SAC signaling has been correlated with levels of
unattached kinetochores. Thus, increasing the number of unattached kinetochores only
slightly could prolong mitotic arrest (20–22). An increase of BUBR1 positive kinetochores
in HCC366 cells exposed to paclitaxel and depleted of CASC1 suggest that CASC1 may be
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supporting mitotic slippage by promoting microtubule-kinetochore attachments and
reducing SAC strength (Figure 3E).
We further examined the impact of siCASC1 on microtubules in HBEC3KT alone, or
following stable depletion of p53 in the absence (HBEC3KT-p53) and presence of
oncogenic K-RAS (HBEC3KT-p53RASV12) (23). Here, we found that CASC1 was
essential for microtubule polymerization in all settings, but only essential for viability
following depletion of p53, thus suggesting the tumor-specific dependency on CASC1 for
viability can be driven by a loss of tumor suppressor activity (Supplemental Figure 4D &
4E). Taken together, these findings suggest that combinatorial regimens that incorporate
multiple anti-tubulin agents may enhance or restore sensitivity to NSCLC.
TRIM69 is a centrosomal and microtubule associated protein essential for mitotic spindle
formation
TRIM69 is a member of the TRIpartite Motif Containing (TRIM) protein family, which
contains a RING E3 ligase domain, B box and coiled-coil domains (24). Two isoforms exist,
A and B, with only the TRIM69A isoform containing a RING domain (Supplemental Figure
5A). Indicative that TRIM69A is an E3 ligase, we detected autoubiquitination of TRIM69A
in an in vitro ubiquitination assay (Supplemental Figure 5B). We found that TRIM69
depletion, similar to CASC1, activated cell death signaling alone or in the presence of
paclitaxel in multiple sensitive and resistant NSCLC backgrounds, with the exception of
H2887. This defect was not observed in normal HBEC3KT cells (Figure 4A), thus
implicating a dependency on TRIM69 for tumor cell survival. At the single cell level, we
observed a number of mitotic defects including: 1) micronucleation (A549), 2) paclitaxel-
enhanced micronucleation (H1299) and 3) multipolar spindles in the presence of paclitaxel
(HCC366 & H1299) (Figure 4B and Supplemental Figure 5C). Depletion of TRIM69 also
increased BUBR1 occupancy at kinetochores in paclitaxel-treated HCC366 cells (Figure
4C). Thus, we conclude that TRIM69 is essential for mitotic fidelity and may be essential
for the proper attachment of microtubules to kinetochores.
To further elucidate the mitotic function of TRIM69, we examined the localization of both
isoforms of TRIM69 during the cell cycle. Examination of cells overexpressing myc-
TRIM69A revealed localization to microtubules during interphase and centrosomes during
mitosis (Figure 5A). Overexpressed myc-TRIM69A also induced microtubule bundling,
rendering microtubules resistant to nocodazole and leading to the generation of
micronucleated cells (Figure 5A and Supplemental Figure 5D). The localization of myc-
TRIM69A to microtubules and centrosomes was dependent upon an intact RING domain as
mutation of canonical cysteines in the zinc finger of TRIM69A abrogated microtubule and
centrosomal localization of the overexpressed construct, indicating that the localization of
TRIM69A is dependent upon E3-ligase activity and/or interaction partners (Figure 5A).
Consistent with this finding, myc-TRIM69B, which lacks the RING domain, was dispersed
throughout the cytoplasm during the cell cycle and did not display microtubule localization
or induce alterations in microtubule stability (Figure 5A, Supplemental Figure 5D). These
data suggest that TRIM69 may play a critical role in supporting mitotic fidelity.
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We next studied the dynamics of myc-TRIM69A localization during the cell cycle, using
H1299 cells with stable expression of myc-TRIM69A. In this setting, we found that myc-
TRIM69A is recruited to centrosomes during prometaphase where it remains through
telophase (Figure 5B and Supplemental 5E). myc-TRIM69A also associated with
endogenous pericentrin in cells arrested in mitosis (Supplemental Figure 5F). The
centrosomal localization of TRIM69A was further bolstered by proteomics data sets that
indicate interactions between TRIM69 and a number of mitotic proteins, including
centrosomal and cytoskeletal components (25–36) (Supplemental 5G). Indeed depletion of
two centrosomal proteins that putatively interact with TRIM69, MYPT1 and GNAI3,
attenuate centrosomal localization of myc-TRIM69A during mitosis (Figure 5C).
Tumor cells frequently amplify centrosomes, which can be induced by tumor suppressors
and/or oncogenes. As multiple centrosomes can lead to multipolar mitosis, mitotic defects
and cell death, tumor cells depend upon mechanisms that promote centrosomal clustering for
cell survival (37). Proteomic studies suggest that TRIM69 interacts with the 8-member
Augmin complex (also known as HAUS), which is essential for centrosomal clustering (31,
37). To evaluate a functional interaction between TRIM69 and the HAUS complex, we
depleted HAUS1 in H1299 cells in the presence and absence of myc-TRIM69A. We find
that spindle multipolarity induced by inhibition of HAUS1 can be reversed by
overexpression of myc-TRIM69A, indicating that TRIM69A can promote centrosomal
clustering (Figure 5D). Thus, inhibition of TRIM69A may enhance the vulnerability of
tumor cells to paclitaxel by attenuating centrosome clustering, which may prolong mitotic
arrest and allow for the reengagement of cell death signaling.
CASC1 and TRIM69 are required for in vivo tumor growth
We next determined whether CASC1 and TRIM69 were essential for growth of tumors in
vivo. Specifically, to achieve stable depletion of CASC1 and TRIM69, we introduced
shRNAs targeting GFP, CASC1 or TRIM69 into HCC366 cells (Figure 6A). These cells
were subcutaneously injected into immunodeficient mice, and we observed attenuation in
growth of tumors expressing shTRIM69 and shCASC1 (Figure 6B and C). Indicating that
the depletion of CASC1 or TRIM69 in vivo was sufficient to reduce mitotic fidelity, H&E
staining on excised tumors revealed extensive micronucleation and aberrant mitotic figures
(Figure 6D). Furthermore, TUNEL staining on tissue sections revealed enhanced cell death
(Figure 6E). Taken together, these findings indicate that CASC1 and TRIM69 suppression is
sufficient to impact mitotic fidelity and viability in vivo.
Discussion
While genomic studies have begun to isolate cohorts of patients that may be selectively
sensitive to precision therapeutics, the majority of NSCLC patients are administered
standard chemotherapeutic regimens that are comprised of DNA damage agents and anti-
mitotics. These regimens are non-curative and in 70% of cases fail to reduce tumor burden
(2, 3). The underlying basis for the intrinsic resistance of NSCLC to standard chemotherapy
is poorly understood. Here, we use a genome-wide RNAi approach to define the molecular
components that deflect cell death in the presence of mitotic damage. This work resulted in a
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number of new principles regarding chemoresistance and mitosis in tumor cells. First, a
common feature to uncouple tumor cell death from an insurmountable spindle defect is
mitotic slippage. Second, inhibition of specific proteins can increase mitotic transit time
>20%, which is sufficient to activate cell death. Third, CASC1 is a novel regulator of
microtubule dynamics that is essential for tumor, but not normal cell survival. Fourth,
TRIM69 is a novel mitotic centrosomal resident protein that supports centrosomal
clustering. In contrast to a previous screen in H1155 sensitive cells, we did not return
multiple components of the γTURC or kinetochore complexes, suggesting that perturbing
spindle assembly in general is not sufficient to enhance sensitivity in NSCLC cells resistant
to paclitaxel(12). These findings suggest a new therapeutic strategy for chemoresistant
NSCLC: combining anti-mitotic agents, such as paclitaxel, with agents, such as small
molecule inhibitors of the APC/Cyclosome may enhance the potency of these first-line
agents with limited impacts on normal tissues.
Many tumor cells exhibit a brief SAC dependent arrest and mitotic escape following
exposure to spindle poisons in vitro and in vivo (6, 38). The frequency of this behavior
suggests that tumor evolution may generally select for variants that are capable of bypassing
prolonged mitotic arrest. Oncogenic changes such as p53 loss, EGFR activation or K-RAS
mutation can induce mitotic spindle and centrosomal alterations, which could conceivably
disrupt mitotic progression and lead to cell death in pre-tumorigenic lesions (39–41). Thus,
those pre-neoplastic variants that bypass mitotic arrest could have a selective advantage, if
they retain fecundity. A collateral consequence of this relationship would be an intrinsic
resistance to anti-mitotic chemotherapeutics. Our work supports the hypothesis that
reengaging a prolonged mitotic arrest can enhance sensitivity to anti-mitotics (6, 9). We find
that elevation of mitotic transit time by 20–50% is sufficient to switch a paclitaxel resistant
setting to a sensitive one. However, frank inhibition of the APC/C, through depletion of
CDC20, is highly lethal in tumor cells and likely normal cells, given the requirement for
CDC20 to activate the APC/C (9). Thus, single agent targeting of the APC/C could have a
narrow or non-existent therapeutic window. Our finding that ANAPC5 depletion can exhibit
a synthetic lethal interaction with paclitaxel, suggests that tumor cells may have an enhanced
sensitivity to APC/C inhibition that may be exploited by combining sub-lethal inhibition of
APC/C with low dose paclitaxel to produce a synthetic phenotype.
We also define a mitotic and microtubule role for the human CASC1 protein in tumor cells.
While this gene has been linked with murine lung tumorigenesis, any functional role in
human tumorigenesis has not been demonstrated. We find that tumor cells require CASC1
for microtubule polymerization and inhibition of CASC1 potentially impacts microtubule
availability for the alignment of chromosomes, thereby increasing the number of unattached
kinetochores and prolonging the SAC. The heightened dependency on tubulin regulation in
tumor cells could be driven by oncogenic stress that may increase centrosomal clustering
defects and attachment errors, thus creating an environment in which mild disruptions to the
microtubule network can wreak havoc on chromosome segregation in tumor cells. As a
recent reports suggest that mitosis is compromised in K-RAS backgrounds, the genetic link
between CASC1 and K-RAS may allow for mitigation of transformation induced mitotic
defects by increasing the expression of a microtubule regulatory protein in concert with an
oncogene (40). Importantly, these finding suggests that one mechanism for prolonging the
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SAC in tumor cells may be to compromise microtubule function in parallel, but independent,
manners by combining anti-tubulin agents.
TRIM69A is an E3 ligase with only limited characterized function, which we implicate as
critical for mitotic fidelity. Specifically, TRIM69A appears to promote centrosomal
clustering, which is an essential process to prevent multipolar spindles and decreased mitotic
fidelity (37, 42, 43). Thus, interfering with centrosomal clustering may be a route to
sensitize resistance cells to paclitaxel. Furthermore, the dependency of TRIM69 on MYPT1
and GNAI3 for centrosomal localization implicates TRIM69 in the regulation of
phosphatase and receptor-independent G(ialpha) signaling during mitosis. MYPT1, which is
localized to the spindle, kinetochores and centrosomes, is thought to regulate SAC
checkpoint silencing though dephosphorylation of Aurora B and BUB1 (44–46). GNAI3 and
other G(ialpha) subunits have been localized to the centrosome and depletion of GNAI3
induces cytokinesis defects, while overexpression increases mitotic transit time (47). Thus,
TRIM69A activity may be essential for coordinating multiple molecular events that promote
bipolar spindle formation and allow for rapid checkpoint silencing. Investigation into the
role of TRIM69A regulation may reveal additional mechanisms governing spindle
alignment and centrosome clustering.
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(A) Paclitaxel dose curves in indicated NSCLC cell lines. Each point is the mean ± Standard
Error of the Mean (SEM) for 3 independent experiments. (B) Whole cell lysates (WCLs)
from HCC366 and H1155 exposed to paclitaxel for 48 hours were immunoblotted as
indicated. (C) Immunostaining of HCC366 cells treated for 24 hours. Arrowheads indicate
micronucleated cells. Scale = 5 μm or 15 μm (right panel). (D) Single-cell lineage tracing of
HCC366 cells stably expressing GFP-H2B (HCC366-GFP-H2B) for 48 hours post-
paclitaxel exposure. Each circle represents a single cell. Bar is mean mitotic transit time,
which is also indicated. Right panel: Cells were transfected with indicated siRNAs for 48
hours prior to drug exposure. (E) Quantitation of single-cell lineage tracing of HCC366-
GFP-H2B micronucleates post exposure to 10 nM paclitaxel. Bars represent mean ± range
for 100 cells over 2 experiments. (F) H&E staining of HCC366 subcutaneous tumor
xenografts treated as indicated. Arrowheads specify micronucleated cells. Scale = 40 μm.
Zoomed images are of white boxed area.
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(A) Graph of relative mitotic transit time (y) vs. relative caspase-3/7 activity (APO-ONE®)
in HCC366 cells exposed to paclitaxel. A subset of siRNA gene targets is indicated. (B)
Colony formation assay in HCC366s exposed to 10 nM paclitaxel for 48 hours. Bars
represent mean ± SEM from n=3 independent experiments. (C) HCC366-GFP-H2B cells
were transfected with indicated siRNAs for 48 hours followed by exposure to 10 nM
paclitaxel. Live cell imaging commenced with paclitaxel treatment and single-cell lineage
traces of 50 cells from 2 independent experiments were measured. (D) As in C, but in the
presence of siMAD2. (E) WCLs from HCC366 cells transfected for 48 hours followed by
exposure to vehicle or 10 nM paclitaxel for 48 hours were immunoblotted with indicated
antibodies. (F) WCLs from non-tumorigenic HBEC3KT (N) and HCC366 (T) cells treated
as in 2E were immunoblotted with indicated antibodies. (G) Left panel: Relative cleaved
caspase-3/7 activity (APO-ONE®) in HCC366s treated with vehicle, 10 nM paclitaxel or 2.5
μM proTAME for 24 hours. Bars represent mean ± SEM for n=9 independent experiments.
** P <0.01 *** P < 0.0001 (unpaired two-tailed student's t-test). Right panel: Immunoblot of
WCLs of HCC366s treated as in left panel.
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(A) WCLs of NSCLC cells immunoblotted with indicated antibodies following siRNA
transfection for 48 hours and subsequent treatment as indicated for 48 hours. siPLK1 was
used as a positive control for cleaved caspase-3 detection in HBEC3KT cells. (B) As in A,
except paclitaxel treatment was 24 hours prior to immunostaining. Scale = 5 μm. (C) Top
panel: H1299 cells were transfected for 72 hours with indicated siRNAs followed by
glutaraldehyde fix and immunostained. Scale =15 μm. Bottom panel: Immunoblots of
H1299 cells following an in vivo polymerized tubulin assay (D) In vivo polymerized tubulin
assay in H1299 cells transfected for 72 hours. Lysates were immunoblotted with indicated
antibodies. (E) HCC366 cells treated as in B, were fixed in cold methanol and
immunostained as indicated. Scale = 5 μm. BUBR1 foci were counted by manual inspection
in 60 cells per experiment in 3 independent experiments. Bar indicates mean. *** P < 0.001,
Mann-Whitney t-test.
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(A&B) As in 3A&B. Scale bars = 10 μm for A549 and H1299, 5 μm for HCC366. (C) As in
3E. ** P <0.05.
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(A) HeLa cells transfected with indicated cDNAs for 48 hours were fixed and
immunostained. Scale = 5μm. Right panel: Quantitation of cells from (A). Bars represent
mean ± range for n=2 independent experiments. (B) Immunostaining of H1299-myc-
TRIM69A representing each stage in the cell cycle based on nuclear morphology. Scale bar
= 5 μm. (C) H1299 cells stably expressing myc-TRIM69A were transfected with indicated
siRNA for 72 hours and immunostained with indicated antibodies. Plots represent relative
fluorescence of myc-TRIM69A at centrosomes in > 150 cells across 3 independent
experiments. *** P <0.0001 by two-tailed Mann Whitney test. Scale = 5 μm. (D) Left panel:
H1299 cells were immunostained with indicated antibodies following siRNA transfection
for 72 hours. Scale = 5 μm. Middle panel: Quantitation of cells from (D). Bars represent
mean ± range from 2 independent experiments. Right panel: Bars represent mean mRNA
expression levels of HAUS1 72 hours post-transfection.
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(A) Bars represent mean mRNA expression levels ± range of CASC1 and TRIM69 in
HCC366 cells expressing indicated hairpins from 2 independent infections. (B) Tumor
growth curves for mice harboring HCC366s expressing indicated shRNAs. shGFP n=9,
shCASC1 n=9 and shTRIM69 n=7. Mean ± standard deviation (SD). (C) Tumors expressing
indicated short hairpins were excised 96 days following injection. Left panel: Bars represent
mean mass of tumors ± SEM; shGFP n=7, shCASC1 n=10, shTRIM69 n=8. Right:
Representative images of excised tumors. (D) Tumors from (B) were sectioned and H&E
stained. Left: Quantitation of micronucleated cells in tumor sections. 6 independent tumors
were examined for each indicated shRNA. Right: Representative images of H&E stained
tumor sections. Scale = 50 μm. White arrowheads indicate micronucleated cells. Blue
arrowheads indicate aberrant mitotic cells. (E) Tumors from (B) were sectioned and TUNEL
stained. Bars indicate mean TUNEL positive cells ± SEM from 6 tumors for each shRNA
condition. For all panels, ** P <0.01. *** P < 0.0001 (unpaired two-tailed student's t-test).
Sinnott et al. Page 21
Cancer Res. Author manuscript; available in PMC 2015 July 15.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
